Amalgamated Bank Sells 5 Shares of Chemed Corp. (NYSE:CHE)
Amalgamated Bank lowered its stake in Chemed Corp. (NYSE:CHE) by 0.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 2,141 shares of the company’s stock after selling 5 shares during the period. Amalgamated Bank’s holdings in Chemed Corp. were worth $391,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also modified their holdings of CHE. BlackRock Inc. boosted its stake in Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock worth $357,341,000 after buying an additional 1,954,653 shares in the last quarter. Norges Bank purchased a new stake in Chemed Corp. during the fourth quarter worth $38,052,000. Vanguard Group Inc. boosted its stake in Chemed Corp. by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock worth $328,070,000 after buying an additional 125,018 shares in the last quarter. Neuberger Berman Group LLC boosted its stake in Chemed Corp. by 2.2% in the first quarter. Neuberger Berman Group LLC now owns 1,060,403 shares of the company’s stock worth $193,725,000 after buying an additional 23,306 shares in the last quarter. Finally, Seizert Capital Partners LLC bought a new stake in Chemed Corp. during the first quarter worth approximately $3,325,000. Institutional investors own 98.33% of the company’s stock.
Shares of Chemed Corp. (NYSE CHE) traded up 0.70% during midday trading on Tuesday, reaching $198.79. 72,928 shares of the company’s stock traded hands. The stock’s 50 day moving average is $203.00 and its 200-day moving average is $190.92. The company has a market capitalization of $3.18 billion, a PE ratio of 49.32 and a beta of 1.14. Chemed Corp. has a 52 week low of $130.05 and a 52 week high of $216.01.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.89 by $0.26. The company had revenue of $415.06 million during the quarter, compared to the consensus estimate of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.80 EPS. On average, analysts forecast that Chemed Corp. will post $8.20 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Monday, August 14th will be paid a dividend of $0.28 per share. This is an increase from Chemed Corp.’s previous quarterly dividend of $0.26. The ex-dividend date of this dividend is Thursday, August 10th. This represents a $1.12 annualized dividend and a yield of 0.56%. Chemed Corp.’s dividend payout ratio is presently 26.07%.
WARNING: “Amalgamated Bank Sells 5 Shares of Chemed Corp. (NYSE:CHE)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/08/chemed-corp-nyseche-stake-decreased-by-amalgamated-bank-updated-updated-updated.html.
A number of analysts recently commented on the stock. BidaskClub cut shares of Chemed Corp. from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 22nd. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Royal Bank Of Canada reissued a “hold” rating and set a $209.00 price target on shares of Chemed Corp. in a research report on Monday, July 31st. Oppenheimer Holdings, Inc. raised their price target on shares of Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. Finally, Zacks Investment Research raised shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 target price for the company in a report on Friday, July 28th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $218.33.
In other Chemed Corp. news, insider Kevin J. Mcnamara sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the transaction, the insider now owns 173,801 shares of the company’s stock, valued at approximately $34,961,809.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director George J. Walsh III purchased 1,000 shares of the business’s stock in a transaction on Monday, June 26th. The stock was purchased at an average cost of $204.56 per share, with a total value of $204,560.00. Following the acquisition, the director now owns 7,908 shares in the company, valued at $1,617,660.48. The disclosure for this purchase can be found here. 5.32% of the stock is owned by corporate insiders.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Stock Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related stocks with our FREE daily email newsletter.